<DOC>
	<DOCNO>NCT00002900</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : This clinical trial study effect chemotherapy heart function treat woman breast cancer negative axillary lymph node undergoing treatment SWOG-8897 clinical trial .</brief_summary>
	<brief_title>SWOG-9342 Chemotherapy Treating Women Enrolled SWOG-8897 Clinical Trial</brief_title>
	<detailed_description>OBJECTIVES : - Compare frequency subclinical congestive heart failure measure rest MUGA 5-8 10-11 year randomization woman receive adjuvant chemotherapy cyclophosphamide , methotrexate , fluorouracil cyclophosphamide , doxorubicin , fluorouracil protocol SWOG-8897 . - Estimate frequency late cardiac effect ( congestive heart failure , cardiac ischemic event , clinical symptom ) patient treat regimen . - Monitor prospectively incidence annual cardiac event fifth tenth year randomization patient regimens . OUTLINE : This multicenter study . The treat physician completes patient cardiovascular routine history physical examination questionnaire baseline yearly . Patients undergo rest MUGA scan 5-8 10-11 year registration protocol SWOG-8897 . The first scan must perform within 3 month prior enrollment within 1 month registration current study , second scan must do tenth year follow-up within 3 month prior enrollment 1 month anniversary registration current study . PROJECTED ACCRUAL : A total 420 patient accrue study . After initial accrual complete , approximately 50 additional patient accrue 10 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cardiotoxicity</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Women register Arm I , II , III , IV protocol SWOG8897 complete least 1 course assign chemotherapy Completion tamoxifen therapy require Registration current study require 5.258 year 1011 year randomization protocol SWOG8897 Patients must diagnose diseasefree prior recurrence registration protocol SWOG8897 Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : Pre postmenopausal Performance status : Not specify Life Expectancy : At least 5 year Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : Pregnant nursing woman eligible nuclear medicine ( MUGA ) portion study Fertile patient must use effective contraception 1 month MUGA PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No prior chemotherapy second primary malignancy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy second primary malignancy Surgery : Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>ductal breast carcinoma</keyword>
	<keyword>cardiac toxicity</keyword>
</DOC>